X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Phase 1b expansion study follows the Phase 1a study, an open label, multicenter, dose escalation clinical trial designed to assess the safety and tolerability of TTX-080 as monotherapy.
Lead Product(s): TTX-080,Pembrolizumab
Therapeutic Area: Oncology Product Name: TTX-080
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
Details:
Gilead can exercise its option to acquire the remainder of Tizona following the readout of a Phase 1b study of Tizona’s investigational antibody, TTX-080, or earlier if Gilead decides to do so.
Lead Product(s): TTX-080
Therapeutic Area: Oncology Product Name: TTX-080
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $1,550.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 21, 2020
Details:
TTX-080 prevents the suppression of both innate and adaptive immune activity and has the potential to enhance anti-tumor responses. Tizona plans to evaluate TTX-080 as both a monotherapy and in combination therapy in advanced cancers in a Phase 1 clinical trial.
Lead Product(s): TTX-080
Therapeutic Area: Oncology Product Name: TTX-080
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
